Nautilus Biotechnology Inc (NAUT) reports a significant decrease in operating expenses and unveils promising collaborations, while preparing for increased investment in 2026.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results